跳到主要內容

WG Biotech ApS 的 Form 4 申報

Y-mAbs Therapeutics, Inc.(YMAB),2023/12/11 申報

申報編號
0001104659-23-125055
申報時間
2023/12/11
交易日
2023/12/7-12/11
申報延遲
4 天
10b5-1 計畫
沒有勾選

這份申報列了 3 筆非衍生性交易。公開市場買進合計 $89.1 萬。交易後 4 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
WG Biotech ApSCIK 0001753193董事

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2023/12/7Common StockP買進取得+6,183$6.50F1+$40,189.54,431,412直接
2023/12/8Common stockP買進取得+18,503$6.99F2+$129,335.974,449,915直接
2023/12/11Common stockP買進取得+102,863$7.01F3+$721,069.634,552,778直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

This transaction was executed in multiple trades each at price of $6.50. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

表 I 有 1 筆交易的價格引用這則附註。

F2

This transaction was executed in multiple trades at prices ranging from $6.90 to $7.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

表 I 有 1 筆交易的價格引用這則附註。

F3

This transaction was executed in multiple trades at prices ranging from $6.86 to $7.15. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

表 I 有 1 筆交易的價格引用這則附註。

備註

Johan Wedell-Wedellsborg is the majority owner of WG Biotech ApS and has sole voting and dispositive power over the shares of the Issuer held by WG Biotech ApS. Mr. Wedell-Wedellsborg serves as a director of the Issuer. In connection therewith, WG Biotech ApS may be deemed to be a director by deputization of the Issuer solely for purposes of Section 16(a) of the Exchange Act. As a result, WG Biotech ApS is listed as a "Reporting Person" in Item 1 and the "Director" box is marked in Item 5 of this Form 4. This filing shall not be deemed an admission by Reporting Person on this Form 4 that such person is a director of the Issuer by deputization.

看 SEC EDGAR 上的完整原文 (在新分頁開啟)